LYB LyondellBasell

Q3 2025 10-Q

Filed: Oct 31, 2025Period ending Sep 30, 2025

Health Care

Industrial Organic ChemicalsSEC EDGAR

LyondellBasell (LYB) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Q3 2025 revenue $7.73B, up 1% QoQ; down 10% YoY from $8.58B (Q3 2024 est. by arithmetic)
• Operating loss $731M Q3 2025 vs income $2,515M YoY; margin swung from ~9.83% to -9.46% (calculated)

+3 more insights

Risk Factors

• No material changes to risk factors from 2024 10-K for fiscal 2025 quarter
• Commodity price volatility risk carried forward impacting profitability

+2 more insights

Quarterly Financial Summary
XBRL

Revenue

$7.7B

▼ -25.1% YoY▲ +0.9% QoQ

Net Income

-$890M

▼ -255.3% YoY▼ -873.9% QoQ

Operating Margin

-9.5%

▼ -1723bp YoY▼ -1318bp QoQ

Net Margin

-11.5%

▼ -1707bp YoY▼ -1302bp QoQ

ROE

-8.4%

Total Assets

$33.8B

EPS (Diluted)

$-2.77

▼ -258.3% YoY▼ -914.7% QoQ

Operating Cash Flow

$983M

▲ +46.7% YoY▲ +180.1% QoQ

Source: XBRL data from LyondellBasell Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on LyondellBasell

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.